Quez et al.24 (1988), USA |
Quasi-experimental. Hospital-based. |
52.5 |
30 patients |
Non-randomized. Treatment with placebo and indapamide. |
“Well being-ill being” Clinical Observation Scale
|
Clinical outcome |
Administration of indapamide |
2.17 point gain on the well-being scale. Average reduction in PA 25.7/16.2 mmHg. |
5c
|
Ameling et al.1 (1991), Holland |
Randomized, double-blind clinical trial. Community-based. |
47 |
Cases: 331. Controls: 137 |
Randomized. Cases: people with PAD > 95 mm/Hg. Controls: people with PAD < 95 mm/Hg. |
Amsterdam Mood List (ASL); Inventory Physical state
|
Clinical outcome |
Administration of betaxolol |
With no difference in quality of life among the groups. |
9d
|
Lee et al.18 (1992), USA |
Randomized, double-blind clinical trial. Community-based |
48 |
620 patients |
Randomized. Three groups: 1/3 received captopril, 1/3 methyldopa, 1/3 propranolol. |
The General Well Being Adjustment Scale (GWB) |
Response from the patient |
Administration of captopril, methyldopa, propranolol |
With no difference in quality of life among the groups. |
8d
|
Novo et al.22 (1993), Italy |
Multicenter trial. Hospital-based. |
68.33 |
125 patients |
Non-randomized. 58.9% used captopril and 41.1% captopril with hydrochlorothiazide. |
Quality of Life Questionnaire (developed by the authors) |
Clinical outcome |
Administration of captopril HCTZ |
Improvement in all quality of life parameters except libido. |
6c
|
Testa et al.34 (1993), USA |
Randomized multicenter clinical trial. Hospital-based. |
64.4 |
Cases: 192. Controls: 187 |
Randomized. Cases: received captopril. Controls: received enalapril. |
Scales: Psychological Well-being; General Perceived Health
|
Clinical outcome |
Administration of captopril and Enalapril |
0.11 unit gain in quality of life total with captopril. 0.11 unit loss in the group with enalapril, leading to negative changes in sexual function. |
9d
|
McCorvey et al.20 (1993), USA |
Randomized, double-blind clinical trial. Community-based. |
66 |
17 patients |
Randomized. 17 patients who used placebos and antihypertensive agents. |
The Nottingham Health Profile
|
Tablet count |
Administration of HCTZ, propranolol and enalapril |
Difficulties sleeping were frequent when using antihypertensive medications compared with placebo, which were greater when using propranolol. |
7d
|
Paran, Anson, Neumann23 (1996), USA |
Randomized, non-blinded clinical trial. Hospital-based. |
54 |
Cases: 53 Controls: 80 |
Randomized. Cases: treated with captopril. Controls: treated with beta-blockers. |
Quality of Life Questionnaire (developed by the authors) |
Clinical outcome |
Administration of captopril |
Improved psychological well-being in both groups. Decline in social activities and perceptions on health deteriorated in the control group. |
8d
|
Cleophas et al.8 (1997), Netherlands |
Randomized, double-blinded multicenter clinical trial. Hospital-based. |
58.6 |
Cases: 70 Controls: 62 |
Randomized. Cases: use of celiprolol. Controls: use of atenolol. |
The Bulpitt and Flecher Questionnaire of Quality of Life
|
Tablet count |
Administration of celiprolol and atenolol for 24 weeks |
Worsening in sexual function for both groups, which was more pronounced in those using atenolol. Atenolol made patients less alert, requiring more hours of sleep. |
8d
|
Barón-Riviera et al.2 (1998), Mexico |
Randomized clinical trial. Community-based. |
51.8 |
Cases: 68 Controls: 71 |
Randomized. Cases: educational intervention. Controls: standard consultation. |
Índice de cambio en la calidad de vida
|
Clinical outcome, response by patient |
Educational intervention on hypertension, nutrition and physical activity |
There were changes in the perception of quality of life and sexual functioning in the case group. The degree of improvement in physical strength and mood was higher in the experimental group. |
7d
|
Vivian36 (2002), USA |
Randomized clinical trial. Hospital-based. |
64.7 |
Cases: 26 Controls: 27 |
Randomized. Cases: medical care + pharmaceutical care. Controls: medical care. |
SF-36 Short-Form Health Survey
|
Tablet count and patient response |
Pharmaceutical care management |
Patients in the control group reported greater bodily pain scores compared to the case group. |
7d
|
Cotê, Farris, Feeny10 (2003), Canada |
Longitudinal. Community-based. |
65.6 |
664 patients |
Cases: 100 hypertensive patients. Controls: 199 high-risk individuals and 365 elderly patients. |
SF-12 Short Form Health survey
|
Morisky’s instrument
|
- |
Physical and mental components were positively correlated with treatment adherence. |
7c |
Dahlöf et al.11 (2005), USA |
Randomized, double-blind clinical trial. Hospital-based. |
51.6 |
Cases: 300 Controls: 545 |
Randomized. Cases: use of felodipine + metoprolol. Controls: use of enalapril or placebo. |
The Psychological General Well-being Index (PGWB) |
Clinical outcome |
Administration of felodipine + metropolol or enalapril or placebo |
The total average quality of life scores were relatively high in all treatment groups at the beginning of the study, and remained relatively constant throughout the study. |
9d |
Mohammadi et al.21 (2006), Iran |
Randomized clinical trial. Hospital-based. |
50 |
Cases: 75 Controls: 75 |
1 Health Center was selected to be the case and another to be the control group. |
SF-36 Short-Form Health Survey
|
Questionnaire for measuring the patients compliance
|
Educational program (nature, causes and complications of hypertension) |
Increase of 4 points on quality of life following intervention in the case group and a loss of 2 points in the control group. |
8d
|
Schulz et al.30(2008), USA |
Randomized clinical trial. Community-based. |
58.23 |
440 patients |
Allocation into three groups: low social support (n=169); average social support (n=143); and high social support (n=128). |
SF-36 Short-Form Health Survey
|
Response from the patient |
Program for lifestyle change |
Best quality of life in the vitality and physical health subscales. High attendance at social support group improves quality of life. |
8d
|
Schmidt et al.29 (2008), Germany |
Prospective multicenter observational study. Community-based. |
60.5 |
Cases: 4,252 Controls: 2,805 with chronic disease and 610 with hypertension |
Non-randomized. Cases: hypertensive patients with olmesartan. Controls: patients with chronic disease; and high blood pressure. |
SF-12 Short-Form Health Survey
|
Clinical outcome |
Administration of olmesartan |
After 6 weeks of therapy with olmesartan, the physical component of quality of life improved compared with the untreated group. The mental component showed no difference among the groups. |
7d
|
Bramlage et al.4 (2010), Germany |
Prospective multicenter observational study. Community-based. |
62.8 |
Cases: 8,237 Controls: 3,415 |
Cases: treated with olmesartan+amlodipine. Controls: two distinct databases. |
SF-12 Short-Form Health Survey
|
Clinical outcome |
Administration of Olmesartan + amlodipine |
After 18 weeks of therapy with olmesartan+amlodipine, the scores for the physical and mental component were higher than the control group. |
7d
|
Limab (2012), Brazil |
Prospective observational study. Community-based |
61.7 |
295 patients |
Hypertensive patients at two basic health units. |
SF-36 Short-Form Health Survey
|
Clinical outcome |
- |
People who adhered to treatment had worse HRQoL results compared to those that did not |
5c
|
Luriziére et al.17 (2013), Canada |
Quasi-experimental. Community-based. |
54.15 |
Cases: 21 Controls: 19 |
Cases: even numbers in the order of arrival. Cases: odd numbers in the order of arrival. |
SF-36 Short-Form Health Survey
|
Response from the patient |
Educational program |
Improvement in the quality of life of the group if in the first month of intervention. |
8d
|
Carvalho Siqueira, Sousa7 (2013), Brazil |
Observational case control. Community-based |
61.5 |
Cases: 246 Controls: 87 |
Randomized. Cases: hypertensive individuals. Controls: normotensive individuals. |
SF-36 Short Form Health survey
|
Clinical outcome |
- |
The diagnosis time interfered with the physical and mental aspects. Neither the controlled or uncontrolled PA interfered with quality of life. |
8d
|
Zyould et al.37 (2013), Palestine |
Prospective observational study. Hospital-based. |
58.4 |
410 patients |
Systematic allocation into three groups: low adherence rate (n=151), average adherence rate (n=110), high adherence rate (n=149). |
European Quality of life Scale (EQ-5D-5L) and EQ Visual Analogue Scale (EQ-VAS) |
Morisky eight-item Medication Adherence Scale (MMAS) |
- |
Patients with a high adherence rate had high quality of life values compared to those with a low or average adherence rate. |
6d
|